Quarterly report · Q2

Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥112.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥55.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥97.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥51.2bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥36.3bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥17.6bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥61.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥37.3bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥38.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥62.2bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥24.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.8bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥25.0bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥26.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥12.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥42.7bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥25.8bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥377.7bnat 2022-09-30Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥308.4bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥86.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥291.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥237.7bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥284.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥231.4bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥100.2bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥87.0bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥25.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥18.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥14.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥13.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥35.442022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.582022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥60.092021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.862021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥35.422022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.572022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥60.042021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.832021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio75.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥701m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥231m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥8.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥445m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥179m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.5bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥634m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥14.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.7bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥347m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥185m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-07-01 → 2022-09-30¥22.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-09-30¥40.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥664m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥2m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥18.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥304m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥865m
—segment totalrevenue2022-04-01 → 2022-09-30¥113.9bn
—segment totalrevenue2022-07-01 → 2022-09-30¥55.9bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥111.2bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥54.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.7bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥1.0bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥36.9bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥17.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥1.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥2.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥1.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥520m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥376m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥8.2bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥7.8bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥364m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥338m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥979m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥10.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥5.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥9.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥5.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥483m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥288m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-09-30¥38.4bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2021-07-01 → 2021-09-30¥19.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-09-30¥37.1bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2021-07-01 → 2021-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥622m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-09-30¥16.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2021-07-01 → 2021-09-30¥8.5bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2021-07-01 → 2021-09-30¥11.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2021-07-01 → 2021-09-30¥11.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥12m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥1m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-09-30¥38.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2021-07-01 → 2021-09-30¥25.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥17.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥12.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥17.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥238m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥238m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥2.0bn
—segment totalrevenue2021-04-01 → 2021-09-30¥98.6bn
—segment totalrevenue2021-07-01 → 2021-09-30¥52.0bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥96.2bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥50.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥2.4bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥1.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥62.9bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥37.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 824
ItemContextValueUnit
Purchase of financial assets measured at fair value inv cf IFRSCurrentYTDDuration-737000000JPY
Proceeds from sale of financial assets measured at fair value inv cf IFRSPrior1YTDDuration43000000JPY
Proceeds from sale of financial assets measured at fair value inv cf IFRSCurrentYTDDuration182000000JPY
Proceeds from sale or redemption of financial assets measured at amortised cost inv cf IFRSPrior1YTDDuration1000000000JPY
Proceeds from sale or redemption of financial assets measured at amortised cost inv cf IFRSCurrentYTDDuration1400000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-754000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-1541000000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-662000000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-777000000JPY
Payments for leasehold deposits and guarantee deposits inv cf IFRSPrior1YTDDuration-321000000JPY
Payments for leasehold deposits and guarantee deposits inv cf IFRSCurrentYTDDuration-73000000JPY
Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRSPrior1YTDDuration150000000JPY
Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRSCurrentYTDDuration457000000JPY
Payments for loans receivable inv cf IFRSPrior1YTDDuration-1000000JPY
Payments for loans receivable inv cf IFRSCurrentYTDDuration-3000000JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration516000000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration8000000JPY
Payments for acquisition of subsidiaries inv cf IFRSPrior1YTDDuration-603000000JPY
Payments for acquisition of subsidiaries inv cf IFRSCurrentYTDDuration-9593000000JPY
Purchase of investments accounted for using equity method inv cf IFRSPrior1YTDDuration-480000000JPY
Purchase of investments accounted for using equity method inv cf IFRSCurrentYTDDuration-1021000000JPY
Payments for acquisition of businesses inv cf IFRSPrior1YTDDuration-JPY
Payments for acquisition of businesses inv cf IFRSCurrentYTDDuration-2298000000JPY
Decrease due to loss of control over subsidiaries inv cf IFRSPrior1YTDDuration-2986000000JPY
Decrease due to loss of control over subsidiaries inv cf IFRSCurrentYTDDuration-JPY
Other inv cf IFRSPrior1YTDDuration0JPY
Other inv cf IFRSCurrentYTDDuration2000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-8065000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-18071000000JPY
Dividends paid to owners of parent fin cf IFRSPrior1YTDDuration-8142000000JPY
Dividends paid to owners of parent fin cf IFRSCurrentYTDDuration-10857000000JPY
Dividends paid to non controlling interests fin cf IFRSPrior1YTDDuration-1291000000JPY
Dividends paid to non controlling interests fin cf IFRSCurrentYTDDuration-1790000000JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration-JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration140000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration-1815000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-JPY
Repayments of borrowings fin cf IFRSPrior1YTDDuration-JPY
Repayments of borrowings fin cf IFRSCurrentYTDDuration-142000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-1823000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-1884000000JPY
Proceeds from issuance of shares fin cf IFRSPrior1YTDDuration36000000JPY
Proceeds from issuance of shares fin cf IFRSCurrentYTDDuration50000000JPY
Other fin cf IFRSPrior1YTDDuration81000000JPY
Other fin cf IFRSCurrentYTDDuration24000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-12955000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-14459000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration276000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration3215000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-2149000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass